Prenatal and child vitamin D levels and allergy and asthma in childhood

Julia Sanguesa, Jordi Sunyer, Raquel Garcia-Esteban, Alicia Abellan, Ana Esplugues, Judith Garcia-Aymerich, Monica Guxens, Amaia Irizar, Jordi Julvez, Leire Luque-Garcia, Ana Cristina Rodriguez-Dehli, Adonina Tardon, Maties Torrent, Jesus Vioque, Martine Vrijheid, Maribel Casas*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Early-life vitamin D deficiency may impair immune system development contributing to allergy and asthma onset. Findings from prospective studies are inconsistent. OBJECTIVE: To examine whether maternal and child vitamin D levels are associated with allergic and asthma-related symptoms throughout childhood in a Spanish birth cohort. METHODS: 25-Hydroxyvitamin D3 (25(OH)D3) levels were measured in the serum of pregnant women (N = 2525) and children (N = 803). Information on allergic and asthma-related symptoms was obtained from repeated questionnaires from 1 to 9 years. RESULTS: A total of 19% of mothers and 24% of children had deficient 25(OH)D3 levels (<20 ng/ml). Higher child 25(OH)D3 levels at 4 years were associated with lower odds of atopic eczema from 4 to 9 years (adjusted odds ratio = 0.90; 95% CI = 0.84–0.97 per 5 ng/ml). Higher maternal and child 25(OH)D3 levels were associated with a lower prevalence of late-onset wheezing at the limit of statistical significance (adjusted relative risk ratio (RRRadj) = 0.86; 95% CI = 0.74–1.00 and RRRadj = 0.76; 95% CI = 0.58–1.02 per 5 ng/ml, respectively). All the remaining associations were null. CONCLUSION: Child 25(OH)D3 levels at pre-school age are associated with a reduced odds of atopic eczema in later childhood and both maternal and child levels may reduce the prevalence of late-onset wheezing.

Original languageEnglish
Number of pages7
JournalPediatric Research
DOIs
Publication statusE-pub ahead of print - 3 Sep 2022

Bibliographical note

FUNDING
Cohort INMA Menorca: INMA Menorca was funded by grants from Instituto de Salud
Carlos III (Red INMA G03/176; CB06/02/0041; 97/0588; 00/0021-2; PI061756;
PS0901958; PI14/00677 incl. FEDER funds), CIBERESP, Beca de la IV convocatoria de
Ayudas a la Investigación en Enfermedades Neurodegenerativas de La Caixa, and EC
Contract No. QLK4-CT-2000-00263. Cohort INMA Valencia: INMA Valencia was funded
by Grants from UE (FP7-ENV-2011 cod 282957 and HEALTH.2010.2.4.5-1), Spain: ISCIII
(Red INMA G03/176, CB06/02/0041; FIS-FEDER: PI03/1615, PI04/1509, PI04/1112, PI04/
1931, PI05/1079, PI05/1052, PI06/1213, PI07/0314, PI09/02647, PI11/01007, PI11/
02591, PI11/02038, PI12/00610, PI13/1944, PI13/2032, PI14/00891, PI14/01687, PI16/
1288, and PI17/00663; Miguel Servet-FEDER CP11/00178, CP15/00025, and CPII16/
00051), Generalitat Valenciana: FISABIO (UGP-15-230, UGP-15-244, and UGP-15-249),
and Alicia Koplowitz Foundation 2017. Cohort INMA Sabadell: INMA Sabadell was
funded by grants from Instituto de Salud Carlos III (Red INMA G03/176; CB06/02/0041;
PI041436; PI081151 incl.FEDER funds) PI12/01890 incl. FEDER funds; CP13/00054 incl.
FEDER funds), CIBERESP, Generalitat de Catalunya-CIRIT 1999SGR 00241, Generalitat
de Catalunya-AGAUR (2009 SGR 501, 2014 SGR 822), Fundació La marató de TV3
(090430), Spanish Ministry of Economy and Competitiveness (SAF2012-32991 incl.
FEDER funds), Agence Nationale de Securite Sanitaire de l’Alimentation de
l’Environnement et du Travail (1262C0010), European Commission (261357, 308333,
603794 and 634453). J. Sangüesa holds a PFIS fellowship, funded by the Instituto de
Salud Carlos III through the project FI19/00124 (Co-funded by European Social Fund,
‘Investing in your future’). J.J. and M.C. hold a Miguel Servet contract (CPII19/00015
and CP16/00128, respectively) awarded by the Instituto de Salud Carlos III (co-funded
by the European Social Fund ‘Investing in your future’). Generalitat de Catalunya-CIRIT
1999SGR 00241. We acknowledge support from the Spanish Ministry of Science and
Innovation and the State Research Agency through the ‘Centro de Excelencia Severo
Ochoa 2019-2023’ Program (CEX2018-000806-S), and support from the Generalitat de
Catalunya through the CERCA Program. Cohort INMA-Asturias: this study was funded
by grants from Instituto de Salud Carlos III (Red INMA G03/176 and CB06/02/0041),
FIS-PI042018 incl. FEDER funds, FIS-PI09/02311 incl. FEDER funds, FIS-PI13/02429 incl.
FEDER funds, FIS-PI18/00909 incl. FEDER funds, CIBERESP, Obra Social Cajastur/
Fundación Liberbank and UNIVERSIDAD DE OVIEDO. Cohort INMA-Gipuzkoa: this
study was funded by grants from Instituto de Salud Carlos III (FIS-PI06/0867, FIS-PI09/
00090, FIS-PI13/02187 and FIS-PI18/01142 incl. FEDER funds), CIBERESP, Department
of Health of the Basque Government (2005111093, 2009111069, 2013111089 and
2015111065), and the Provincial Government of Gipuzkoa (DFG06/002, DFG08/001
and DFG15/221) and annual agreements with the municipalities of the study area
(Zumarraga, Urretxu, Legazpi, Azkoitia y Azpeitia y Beasain). The funding sources had
no involvement in the study design, the collection, analysis and interpretation of data
or in the writing of the report and in the decision to submit the article for publication.

Fingerprint

Dive into the research topics of 'Prenatal and child vitamin D levels and allergy and asthma in childhood'. Together they form a unique fingerprint.

Cite this